Cosmos Health Inc.(COSM)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,616 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
COSM Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Cosmos Health Inc. (COSM), a Consumer Staples sector company. 13F Pro's AI-powered ranking engine scores COSM at 26.6/100 on a 32-signal composite quality model, placing it at rank #2,616 of 2,962 stocks — the bottom half of the AI-ranked universe. COSM scores in the top quartile across revenue growth (77.0). Areas of concern include earnings quality (4.5) and balance sheet strength (5.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 29.8/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Cosmos Health Inc. reports quarterly revenue of $19.0M, net income of $-6.1M, free cash flow of $-1.8M. Top institutional holders of COSM by reported 13-F value include UBS Group AG, VANGUARD FIDUCIARY, JANE STREET GROUP, based on the most recent SEC filings. COSM trades on the Nasdaq exchange and files with the SEC under CIK 1474167. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate COSM daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cosmos Health Inc. directly from SEC EDGAR. Cosmos Health Inc.'s 13F Pro composite quality score has ranged between 17 and 33 since 2023, currently 26.6 — an improving long-term trajectory across 60 quarterly and live scoring snapshots.
Revenue
Q2 2026
$19.0M
Net Income
Q2 2026
$-6.1M
Free Cash Flow
Q2 2026
$-1.8M
ROIC
Q2 2026
-49.0%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+19.9% YoYNet Income
-18.3% YoYOperating Income
-7.5% YoYEPS (Diluted)
+46.2% YoYTotal Assets
+20.6% YoYTotal Debt
-8.1% YoYOp. Cash Flow
-9.5% YoYFree Cash Flow
-4.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $65.3M +19.9% | $54.4M +2.0% | $53.4M +6.0% | $50.3M -10.5% | $56.2M +1.5% | $55.4M |
| Net Income | $-19.1M -18.3% | $-16.2M +12.7% | $-18.5M -34.1% | $-13.8M -73.7% | $-8.0M -1070.0% | $820.8K |
| Operating Income | $-16.7M -7.5% | $-15.5M +28.8% | $-21.8M -192.1% | $-7.5M -64.9% | $-4.5M -267.0% | $2.7M |
| EPS (Diluted) | $-0.32 +46.2% | $-0.58 +45.6% | $-1.07 +93.5% | $-16.58 -3390.5% | $-0.47 -1683.3% | $0.03 |
| Total Assets | $65.5M +20.6% | $54.3M -17.7% | $66.0M -3.0% | $68.0M +37.6% | $49.4M +12.7% | $43.8M |
| Total Debt | $3.8M -8.1% | $4.1M -36.9% | $6.5M +29.8% | $5.0M -72.0% | $17.9M +66.2% | $10.8M |
| Operating Cash Flow | $-8.4M -9.5% | $-7.7M +50.6% | $-15.6M -5.1% | $-14.9M -109.5% | $-7.1M +38.3% | $-11.5M |
| Free Cash Flow | $-8.5M -4.5% | $-8.1M +52.0% | $-16.9M -13.4% | $-14.9M -94.6% | $-7.7M +33.9% | $-11.6M |
Get alerted when COSM's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Cosmos Health Inc. including:
Top Institutional Holders of COSM
UBS Group AG
$110.0K594,462 shVANGUARD FIDUCIARY TRUST CO
$61.8K333,842 shJANE STREET GROUP, LLC
$53.4K289,287 shGEODE CAPITAL MANAGEMENT, LLC
$52.1K282,094 shBlackRock, Inc.
$49.5K267,797 shCITADEL ADVISORS LLC
$33.6K182,100 shVANGUARD CAPITAL MANAGEMENT LLC
$32.2K173,966 shNORTHERN TRUST CORP
$10.0K53,887 shSTATE STREET CORP
$8.4K45,243 shSassicaia Capital Advisers LLC
$6.6K36,000 sh
| Fund | Value | Shares |
|---|---|---|
| UBS Group AG | $110.0K | 594,462 |
| VANGUARD FIDUCIARY TRUST CO | $61.8K | 333,842 |
| JANE STREET GROUP, LLC | $53.4K | 289,287 |
| GEODE CAPITAL MANAGEMENT, LLC | $52.1K | 282,094 |
| BlackRock, Inc. | $49.5K | 267,797 |
| CITADEL ADVISORS LLC | $33.6K | 182,100 |
| VANGUARD CAPITAL MANAGEMENT LLC | $32.2K | 173,966 |
| NORTHERN TRUST CORP | $10.0K | 53,887 |
| STATE STREET CORP | $8.4K | 45,243 |
| Sassicaia Capital Advisers LLC | $6.6K | 36,000 |
Companies Similar to COSM
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Local Bounti Corporation/DE
Laird Superfood, Inc.
Limoneira CO
Zevia PBC
Waldencast plc
Westrock Coffee Co
SOLESENCE, INC.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Consumer Staples Companies
View all Consumer Staples →Put COSM on your watchlist
Track score changes the day Cosmos Health Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is COSM a good stock to buy?
13F Pro's AI-powered analysis of Cosmos Health Inc. (COSM) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Consumer Staples sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for COSM are available on the COSM stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. COSM is classified as a small company.
Which hedge funds own COSM?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling COSM. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cosmos Health Inc.'s investment landscape.